Adagio Medical Holdings, INC 8-K filings

Adagio Medical announced a significant 351% increase in revenue for the third quarter of 2024, driven by the introduction of their vCLAS cryoablation catheter, alongside progress in clinical studies and European commercial expansion.

Adagio Medical Holdings, Inc. has filed an amendment to its previous 8-K report to restate audited and unaudited financial statements of its subsidiary, Adagio Medical, Inc., for various periods.

Adagio Medical Holdings has determined that previously issued financial statements for multiple periods should no longer be relied upon due to an error in recording accrued interest, and will be restated.

Adagio Medical has announced several business updates, including the CE Mark approval and European launch of its vCLAS catheter, positive clinical trial data, FDA approval for a pivotal US study, and the closing of a business combination and Nasdaq listing.

Adagio Medical Holdings, formerly Aja HoldCo, Inc., has completed its business combination with ARYA Sciences Acquisition Corp IV, and filed an amendment to its 8-K report including unaudited financial statements.

Adagio Medical Holdings, Inc. begins trading on the Nasdaq after completing its business combination with ARYA IV, focusing on innovative cardiac arrhythmia treatment technologies.